Introduction to the Dupixent Lawsuit

  • Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases. The medicine is currently the subject of a growing number of lawsuits alleging it causes or accelerates the development of cutaneous T-cell lymphoma (CTCL), a rare form of cancer. As of November 2025, the litigation is in early stages, with no settlements or jury verdicts yet.
  • Recent studies on Dupixent and Cancer:  Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.
  • Potential Compensation: People who used Dupixent and were later diagnosed with CTCL may be eligible to file a Dupixent Cancer Lawsuit and potentially be entitled to substantial compensation. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

1. What Is Dupixent?

  • Mechanism of Action: It works by treating the underlying cause of inflammation and is commonly prescribed for people with atopic dermatitis, eczema, asthma, chronic sinusitis, and eosinophilic esophagitis.
  • Potential Compensation: People who used Dupixent and were later diagnosed with CTCL may be eligible to file a Dupixent Cancer Lawsuit and potential entitled to substantial compensation. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

2. What Are the Common Dupixent Side Effects?

COMMON DUPIXENT SIDE EFFECTS

Dupixent Lawsuit

3. What about Dupixent and Cancer?

  • Dupixent and its Intended Use:  Dupixent  is a prescription injection manufactured by Sanofi and Regeneron and first approved by the FDA in 2017. It is commonly prescribed for patients with:
    • Moderate-to-severe eczema (atopic dermatitis)
    • Asthma
    • Cchronic sinusitis with nasal polyps
    • eosinophilic esophagitis
  • Dupixent And Cancer: In recent years, however, Dupixent® has been linked to cutaneous T-cell lymphoma (CTCL), a rare and serious form of non-Hodgkin lymphoma. Studies published in 2024 and 2025 suggest that Dupixent® patients may face a 300% higher risk of developing CTCL yet manufacturers never warned healthcare providers or patients about this risk.
  •  Contact a Dupixent Cancer Lawyer: If you took Dupixent and subsequently developed CTCL or other serious Dupixent side effects or just have general questions, call Dupixent Cancer Lawyer Timothy L. Miles today, free of charge, for a free case evaluation as you may be eligible for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation.  (855) 846-6529 or [email protected].

The word SIDE EFFECTS written on a white notepad on a blue background near a stethoscope, syringe, electronic thermometer and pills. Medical concept used in Dupixent Lawsuit

4. Is there Research that Supports the Link Between Dupixent and Cancer?

Several medical reports and studies including the Nation Library of Medicine have suggested that Dupixent may be tied to an increased risk of CTCL.

    • A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
    • A second study using TriNetX data (Mandel et al., 2024) was published in August 2024 and followed a method similar to the first study by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma.After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).
    • In September 2025, a study led by Sheng-Kai Ma and his team looked at the  patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53).

After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.

  • Acceleration of cutaneous T-cell lymphoma following dupilumab administration
    • Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema

These findings have pushed doctors to re-evaluate how and when to prescribe Dupixent — especially when patients show unusual skin reactions that don’t improve.

5. What Is the Dupixent Lawsuit Status?

  • Dupixent Lawsuit: Individual lawsuits have been filed across the U.S., but they have not yet been consolidated into a formal multidistrict litigation (MDL).
  • First Lawsuit:  The first known Dupixent Lawsuit for wrongful death lawsuit was filed in a federal court in Tennessee in October 2025. The lawsuit alleges the drug caused a woman’s fatal T-cell lymphoma and that the manufacturers failed to provide adequate warnings.
  • No MDL or Class Action: There is currently no formal multidistrict litigation (MDL) or class-action lawsuit. However, legal experts anticipate that cases may be consolidated into an MDL in late 2025 or early 2026 to streamline the legal process if more cases emerge.
  • FDA Investigation: The U.S. Federal and Drug Administration (FDA) is formally investigating the potential link and evaluating whether new cancer warnings should be added to the Dupixent label. The current label does not mention a CTCL risk.
  • Settlements: No settlements have been reached in any Dupixent Lawsuit, and there are no jury verdicts, making it difficult to estimate potential settlement amounts.

A COMPLETE TIMELINE OF SIGNIFICANT EVENTS

Dupixent Lawsuit

6. Who is Eligible for a Dupixent Lawsuit?

Dupixent Lawsuit: You may be eligible if you:

  • Used Dupixent (dupilumab) as prescribed
  • Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
  • Experienced serious Dupixent side effects or worsening symptoms
  • Are within your state’s statute of limitations

7. What is the Compensation in a Dupixent Cancer Lawsuit?

If you are eligible for a Dupixent Cancer Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:

If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions.  Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive.  (855) 846–6529 or [email protected].

8. If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?

  • Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Cancer Lawyer to see if you qualify for a Dupixent Cancer Lawsuit. These are not typical cases any lawyer can litigate. Contact Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about what will happen next.  (855) 846–6529 or [email protected].
  • Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.
  • Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug.  Time is of the essence so give Dupixent Cancer Lawyer Timothy L. Miles a call today.

Medicine concept: text Side Effect on Black chalkboard on grunge wall background, 3D rendering used in FDA approved concept. Rubber stamp with FDA and medicine. 3d illustration used in Dupixent lawsuit

9. How Much Does if Cost to Hire a Dupixent Cancer Lawyer?

  • No Fee:  It does not cost anything to hire a lawyer​ if you are eligible for a Dupixent Cancer Lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
  • Talk with a Lawyer Free of Charge: A lawyer​ can explain the process of a Dupixent Cancer Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Dupixent Cancer Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.

10. Is there a Dupixent Class Action Lawsuit?

  • Dupixent Class Action Lawsuit: As of now, there is no Dupixent class action lawsuit, with almost all Dupixent lawsuits being filed product liability cases on their behalf only, rather than a single class action.
  • Multidistrict Litigation:  In an MDL, the plaintiff maintains his own case and potential compensation, but legal proceedings share a concerted strategy for judicial efficiency. Furthermore, it gives patients across the country to present consistent evidence about Dupixent and cancer risks while keeping their individual right to compensation intact.

Contact Timothy L. Miles Today About a Dupixent Cancer Lawsuit

If you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation.  855/846-6529 or via e-mail at [email protected].(24/7/365).

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Facebook    Linkedin    Pinterest    youtube

 

Logo law office timothy l. miles used in Dupixent Lawsuit